MA49959B1 - Formulation liposomale pour lubrification d'articulation - Google Patents

Formulation liposomale pour lubrification d'articulation

Info

Publication number
MA49959B1
MA49959B1 MA49959A MA49959A MA49959B1 MA 49959 B1 MA49959 B1 MA 49959B1 MA 49959 A MA49959 A MA 49959A MA 49959 A MA49959 A MA 49959A MA 49959 B1 MA49959 B1 MA 49959B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
joint
liposomal formulation
gpl
membrane
Prior art date
Application number
MA49959A
Other languages
English (en)
Other versions
MA49959A (fr
Inventor
Yechezkel Barenholz
Yaniv Dolev
Keren Turjeman
Gadi Sarfati
Maty Ayal-Hershkovitz
Original Assignee
Moebius Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moebius Medical Ltd filed Critical Moebius Medical Ltd
Publication of MA49959A publication Critical patent/MA49959A/fr
Publication of MA49959B1 publication Critical patent/MA49959B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/10—Materials for lubricating medical devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la lubrification des articulations, la composition pharmaceutique comprenant un agent de tonicité non ionique comprenant un polyol, et des liposomes comprenant au moins une membrane comprenant au moins un phospholipide (pl) choisi parmi un glycérophospholipide (gpl), ledit gpl comportant deux chaînes hydrocarbonées en c12 à c18, identiques ou différentes, et d'une sphingomyéline (sm) comportant une chaîne hydrocarbonée en c12 à c18, la composition pharmaceutique étant essentiellement exempte d'un agent pharmaceutiquement actif supplémentaire, l'au moins une membrane présentant une température de transition de phase dans la plage d'environ 20 °c à environ 39 °c et l'articulation présentant une température d'articulation qui est au-dessus de la température de transition de phase.
MA49959A 2017-08-22 2018-08-21 Formulation liposomale pour lubrification d'articulation MA49959B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762548429P 2017-08-22 2017-08-22
PCT/IL2018/050923 WO2019038763A1 (fr) 2017-08-22 2018-08-21 Formulation liposomale pour lubrification d'articulation

Publications (2)

Publication Number Publication Date
MA49959A MA49959A (fr) 2020-07-01
MA49959B1 true MA49959B1 (fr) 2023-07-31

Family

ID=65439381

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49959A MA49959B1 (fr) 2017-08-22 2018-08-21 Formulation liposomale pour lubrification d'articulation

Country Status (25)

Country Link
US (3) US11123293B2 (fr)
EP (2) EP4223284A1 (fr)
JP (2) JP7082336B2 (fr)
KR (2) KR102607729B1 (fr)
CN (2) CN114601799B (fr)
AU (3) AU2018319594B2 (fr)
BR (1) BR112020003767B1 (fr)
CA (2) CA3073368C (fr)
DK (1) DK3672653T3 (fr)
EA (1) EA202090476A1 (fr)
ES (1) ES2948715T3 (fr)
FI (1) FI3672653T3 (fr)
HR (1) HRP20230566T1 (fr)
HU (1) HUE062030T2 (fr)
IL (3) IL272630B2 (fr)
LT (1) LT3672653T (fr)
MA (1) MA49959B1 (fr)
MX (2) MX2020002041A (fr)
MY (1) MY197149A (fr)
PH (1) PH12020500331A1 (fr)
PL (1) PL3672653T3 (fr)
PT (1) PT3672653T (fr)
SG (1) SG11202000773QA (fr)
SI (1) SI3672653T1 (fr)
WO (1) WO2019038763A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782181B (zh) * 2019-02-11 2022-11-01 以色列商莫比斯醫療有限公司 用於關節潤滑的脂質體調配物
JP2021013788A (ja) * 2020-11-10 2021-02-12 株式会社三洋物産 遊技機
MX2024008401A (es) * 2022-01-02 2024-08-19 Moebius Medical Ltd Determinacion del volumen atrapado de un liposoma.
CA3266614A1 (fr) 2023-01-19 2024-07-25 Moebius Medical Ltd. Composition liposomale à action prolongée pour le traitement de la douleur dans des troubles articulaires
KR20250018222A (ko) * 2023-07-26 2025-02-05 차의과학대학교 산학협력단 미토콘드리아가 캡슐화된 세포막 융합유도 리포좀을 포함하는 골관절염 치료를 위한 약학 조성물
IL314549A (en) * 2024-07-25 2026-02-01 Moebius Medical Ltd Liposomal conjugates and their uses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403592A (en) 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
EP0319638A1 (fr) * 1987-12-08 1989-06-14 Estee Lauder Inc. Compositions cosmétiques et pharmaceutiques contenant des liposomes et procédés pour l'utilisation de telles compositions
US5941909A (en) * 1995-02-14 1999-08-24 Mentor Corporation Filling material for soft tissue implant prostheses and implants made therewith
AUPN723395A0 (en) 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
US6379648B1 (en) * 1999-02-01 2002-04-30 The Curators Of The University Of Missouri Biodegradable glass compositions and methods for radiation therapy
US6800298B1 (en) * 2000-05-11 2004-10-05 Clemson University Biological lubricant composition and method of applying lubricant composition
CA2435418A1 (fr) * 2001-01-24 2002-08-01 Mestex Ag Utilisation de substances neurotoxiques pour la production d'un agent servant a traiter les douleurs articulaires
US6509027B2 (en) 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
WO2002078445A1 (fr) * 2001-03-29 2002-10-10 The Scripps Research Institute Formulations comprenant des ingredients actifs pieges et utilisations de ces formulations
JP2005525992A (ja) * 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
WO2003000191A2 (fr) 2001-06-25 2003-01-03 Depuy Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques
US20050123593A1 (en) 2001-06-25 2005-06-09 Jonathan Thompson Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
DE10255106A1 (de) * 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
US7205006B2 (en) 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
DE602005010424D1 (de) 2004-06-03 2008-11-27 Bracco Research Sa Liposomale anordnung für die therapeutische und/oder diagnostische anwendung
JP2008502690A (ja) 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法
US20070071840A1 (en) 2005-09-27 2007-03-29 Sridevi Dhanaraj Method for treatment of cartilage disorders with centella extract
ITPD20060202A1 (it) 2006-05-22 2007-11-23 Univ Degli Studi Trieste Miscele polimeriche di polisaccaridi anionici e cationici e loro impiego
JP5072275B2 (ja) * 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
US20080027554A1 (en) * 2006-07-31 2008-01-31 Talmadge Karen D Kit and methods of treatment of an intervertebral disc
CA2664944C (fr) 2006-09-28 2016-06-14 Hadasit Medical Research Services & Development Limited Utilisation de glycero-phospholipides pour une lubrication des articulations
US8834920B2 (en) 2006-12-21 2014-09-16 Alza Corporation Liposome composition for targeting egfr receptor
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
JP2011512409A (ja) 2008-02-20 2011-04-21 イーエルシー マネージメント エルエルシー 皮膚を美白するための局所組成物及び方法
BR112012032153A2 (pt) * 2010-06-17 2017-08-08 Yeda Res And Development Company Ltd método para a lubrificação de uma ou mais superfícies não biológicas, método para a lubrificação de uma ou mais superfícies de um tecido biológico em um indivíduo mamífero, uso de lipossomas na fase em gel e lipossoma misto
IL206739A (en) * 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
WO2012143876A1 (fr) 2011-04-19 2012-10-26 Anteis S.A. Formulation aqueuse stérile et injectable pour l'administration dans l'espace intra-articulaire d'une articulation intra-articulaire
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
SI2854769T1 (sl) * 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa
CN104688721A (zh) * 2014-10-11 2015-06-10 黄萍 一种含紫杉醇脂质体的抗类风湿性关节炎药物凝胶剂及其制备方法

Also Published As

Publication number Publication date
KR102808544B1 (ko) 2025-05-19
CA3073368A1 (fr) 2019-02-28
US20200170948A1 (en) 2020-06-04
MA49959A (fr) 2020-07-01
MX2020002041A (es) 2020-08-13
KR20230166148A (ko) 2023-12-06
EP3672653A4 (fr) 2021-01-13
US12214077B2 (en) 2025-02-04
IL272630B2 (en) 2023-09-01
IL312816B1 (en) 2026-02-01
JP7082336B2 (ja) 2022-06-08
AU2018319594B2 (en) 2023-06-15
AU2018319594A1 (en) 2020-02-20
US11123293B2 (en) 2021-09-21
PL3672653T3 (pl) 2023-08-14
IL272630A (en) 2020-03-31
CA3219776A1 (fr) 2019-02-28
FI3672653T3 (fi) 2023-06-07
AU2025200077B2 (en) 2026-01-08
US20250114304A1 (en) 2025-04-10
AU2023203309A1 (en) 2023-06-22
SI3672653T1 (sl) 2023-08-31
WO2019038763A1 (fr) 2019-02-28
US20210369613A1 (en) 2021-12-02
EP4223284A1 (fr) 2023-08-09
EP3672653A1 (fr) 2020-07-01
MY197149A (en) 2023-05-26
IL301801A (en) 2023-05-01
CN114601799A (zh) 2022-06-10
CN114601799B (zh) 2023-09-26
BR112020003767B1 (pt) 2023-10-10
EA202090476A1 (ru) 2020-06-29
DK3672653T3 (da) 2023-06-12
CN111065423B (zh) 2022-04-12
PH12020500331A1 (en) 2020-10-05
EP3672653B1 (fr) 2023-03-29
AU2025200077A1 (en) 2025-01-23
CN111065423A (zh) 2020-04-24
IL312816A (en) 2024-07-01
AU2023203309B2 (en) 2024-10-10
ES2948715T3 (es) 2023-09-18
IL301801B1 (en) 2024-06-01
MX2023009082A (es) 2023-08-08
HUE062030T2 (hu) 2023-09-28
KR102607729B1 (ko) 2023-11-29
JP2020531538A (ja) 2020-11-05
LT3672653T (lt) 2023-07-10
PT3672653T (pt) 2023-06-29
SG11202000773QA (en) 2020-03-30
CA3073368C (fr) 2024-01-02
HRP20230566T1 (hr) 2023-08-18
JP7383759B2 (ja) 2023-11-20
IL272630B1 (en) 2023-05-01
NZ761298A (en) 2024-03-22
JP2022110090A (ja) 2022-07-28
KR20200044006A (ko) 2020-04-28
BR112020003767A2 (pt) 2020-09-01
IL301801B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
MA49959B1 (fr) Formulation liposomale pour lubrification d'articulation
MA29573B1 (fr) Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol
Pham et al. Pain management in patients with chronic kidney disease
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
MA53076B1 (fr) Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
MA34253B1 (fr) Composition agrochimique stabilisee
CA2176840A1 (fr) Association d'un compose a activite anti-microbienne et d'un monoalkylether de glycerol
IL190497A0 (en) Ophthalmic emulsions containing prostaglandins
AR125412A2 (es) Composiciones herbicidas
MA42641A1 (fr) Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih
FR3063893B1 (fr) Emulsions doubles huile-dans-huile-dans-eau
MA53665B1 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
MA29907B1 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol et les ionones alpha - et beta-
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
EP4006114A4 (fr) Agent de revêtement pour joint étanche à l'huile
MA39421A (fr) Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes
EP3762006C0 (fr) Huile de krill pour solubiliser des compléments alimentaires peu solubles dans l'eau et des agents pharmaceutiquement actifs
EP3795170C0 (fr) Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne
MA45202B1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
MA37672A1 (fr) Formulation d'agoniste des récepteurs à la somatostatine
EP4299938A4 (fr) Structure d'étanchéité à la graisse d'un joint homocinétique de véhicule, et joint homocinétique la comprenant
MA31541B1 (fr) Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine
JP2011163388A5 (fr)
MA63937B1 (fr) Traitement combiné de lésions cérébrales
TH2001000930A (th) สูตรผสมไลโพโซมสำหรับการหล่อลื่นข้อต่อ